DexCom (NASDAQ:DXCM) Given New $120.00 Price Target at Barclays

DexCom (NASDAQ:DXCM) had its price objective raised by Barclays from $115.00 to $120.00 in a research note published on Friday,Benzinga reports. Barclays currently has an overweight rating on the medical device company’s stock.

A number of other brokerages also recently weighed in on DXCM. Argus lifted their price objective on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, July 31st. Benchmark raised their target price on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $105.00 target price (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Finally, Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $92.91.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $82.29 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom has a 52 week low of $54.11 and a 52 week high of $92.59. The firm has a market cap of $31.05 billion, a PE ratio of 32.27, a price-to-earnings-growth ratio of 1.34 and a beta of 1.48. The firm’s fifty day moving average is $85.82 and its 200-day moving average is $74.65.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a return on equity of 36.96% and a net margin of 19.42%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.61 earnings per share. Sell-side analysts predict that DexCom will post 2.64 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme Sylvain sold 3,638 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares in the company, valued at $4,168,052.64. This represents a 3.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 24,822 shares of company stock worth $2,090,833. 0.28% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Large investors have recently bought and sold shares of the stock. Covestor Ltd raised its position in DexCom by 79.6% in the third quarter. Covestor Ltd now owns 1,282 shares of the medical device company’s stock worth $111,000 after acquiring an additional 568 shares during the period. Caldwell Trust Co boosted its stake in DexCom by 1.8% in the third quarter. Caldwell Trust Co now owns 13,732 shares of the medical device company’s stock valued at $1,185,000 after acquiring an additional 241 shares during the last quarter. Rakuten Investment Management Inc. grew its position in shares of DexCom by 8.7% during the 3rd quarter. Rakuten Investment Management Inc. now owns 101,020 shares of the medical device company’s stock valued at $8,752,000 after acquiring an additional 8,108 shares during the period. Factory Mutual Insurance Co. grew its position in shares of DexCom by 4.8% during the 3rd quarter. Factory Mutual Insurance Co. now owns 563,383 shares of the medical device company’s stock valued at $48,614,000 after acquiring an additional 25,553 shares during the period. Finally, Signature Equity Partners LLC increased its stake in shares of DexCom by 97.3% during the 3rd quarter. Signature Equity Partners LLC now owns 436 shares of the medical device company’s stock worth $38,000 after purchasing an additional 215 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.